Seizure-European Journal of Epilepsy最新文献

{"title":"Identifying hotspots of seizure-related hospital admissions in Australia","authors":"Subramanian Muthusamy ,&nbsp;Albert L G Phan ,&nbsp;Udaya Seneviratne ,&nbsp;Richard Beare ,&nbsp;Velandai Srikanth ,&nbsp;Henry Ma ,&nbsp;Thanh G Phan","doi":"10.1016/j.seizure.2025.03.017","DOIUrl":"10.1016/j.seizure.2025.03.017","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to: (1) map geographic trends of seizure-related hospitalizations across Australia, (2) identify hotspots in hospitalization rates, and (3) assess geographic inequities in access to specialized services for seizure disorders.</div></div><div><h3>Methods</h3><div>Standardized seizure admission ratios (SR) were calculated using publicly available hospital admissions data incorporating the diagnoses of epilepsy, status epilepticus and convulsions for the year 2020–21 in Australia. Forward selection was used to ascertain optimal subset of covariates for spatial regression models. Model fitness was evaluated using Deviance Information Criterion and Watanabe-Akaike Information Criterion. Tiered hospital catchment maps and relationships between hospitals were generated based on proximity and available specialized services. A web-based application was created to view results and includes a search function to identify tiers of hospitals for Australian addresses (<span><span>https://gntem3.shinyapps.io/epilepsyadmissions/</span><svg><path></path></svg></span>).</div></div><div><h3>Results</h3><div>Although the absolute number of hospitalizations was low, the Northern Territory had three local government areas (LGAs) with the highest SRs (e.g., MacDonnell LGA (SR 5.29, <em>n</em> = 50)). Hotspots were more frequently observed in regional and remote LGAs but were also present in urban areas (e.g., Geelong LGA (SR 1.24)). The bestperforming spatial regression model incorporated kidney disease, cancer, diabetes, mental health conditions, and the number of family physicians per 100,000 people as significant covariates.</div></div><div><h3>Conclusion</h3><div>Hotspots of seizure-related hospitalizations are often located in areas with limited access to specialized services, underscoring the geographic inequities in care delivery. Addressing these disparities through further modelling of spatial trends and targeted resource allocation is essential for improving equitable healthcare access for seizure disorders.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 70-76"},"PeriodicalIF":2.7,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Explosive onset focal epilepsies without cortical malformation: A review of a pediatric cohort with pathogenic variations in the GATOR1 complex (DEPDC5, NPRL3 and NPRL2)","authors":"Sarah Baer ,&nbsp;Marie-Thérèse Abi Wardé ,&nbsp;Marie-Aude Spitz ,&nbsp;Lucas Gauer ,&nbsp;Edouard Hirsch ,&nbsp;Vincent Laugel ,&nbsp;Maria Paola Valenti Hirsch ,&nbsp;Carole Lambert ,&nbsp;Amélie Piton ,&nbsp;Caroline Schluth-Bolard ,&nbsp;Julia Scholly ,&nbsp;Margaux Biehler ,&nbsp;Clotilde Boulay ,&nbsp;Anne de Saint Martin","doi":"10.1016/j.seizure.2025.03.013","DOIUrl":"10.1016/j.seizure.2025.03.013","url":null,"abstract":"<div><div>GATOR1 complex genes (<em>DEPDC5, NPRL2, NPRL3</em>) are associated with focal epilepsies, often without cortical malformations or intellectual disabilities. Our study focused on 10 children, with GATOR1 pathogenic variation and negative MRIs, all experiencing focal epilepsy onset between ages 1 and 7 years. Three were initially misdiagnosed with immune encephalitis, with seizure frequencies ranging from 2 per week to 40 per day. The seizures were monofocal and stereotyped in the same child. No recurrent brain localization was found in EEG, clinical data, or MRI. After achieving early developmental milestones, some patients developed cognitive or psychiatric challenges during active seizures. Over 1 to 14 years, three experienced recurrent status epilepticus, triggered by infections or medication changes. Currently, two patients are seizure-free on antiepileptic medications, while six continue to have frequent seizures. Notably, only half showed concordance between EEG and PET scan anomalies. Pathogenic variations included five in <em>DEPDC5</em>, four in <em>NPRL3</em>, and one in <em>NPRL2</em>, with six inherited from parents 3 of them being unaffected. The timeline for genetic analysis requests has significantly shortened over time. In cases of pharmacoresistant monofocal epilepsy with normal MRIs, in children with normal development—especially with a family history—testing for GATOR1 variations should be prioritized.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 25-28"},"PeriodicalIF":2.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143783877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A heterozygous pathogenic RELN variant in autosomal dominant lateral temporal epilepsy","authors":"Si-Lei Fong ,&nbsp;Kheng-Seang Lim ,&nbsp;Mohd Zaki Salleh ,&nbsp;Lay-Kek Teh","doi":"10.1016/j.seizure.2025.03.015","DOIUrl":"10.1016/j.seizure.2025.03.015","url":null,"abstract":"","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 22-24"},"PeriodicalIF":2.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143740075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seizure detection using the wristband accelerometer, gyroscope, and surface electromyogram signals based on in-hospital and out-of-hospital dataset","authors":"Guangming Wang ,&nbsp;Hao Yan ,&nbsp;Wen Li ,&nbsp;Duozheng Sheng ,&nbsp;Liankun Ren ,&nbsp;Qun Wang ,&nbsp;Hua Zhang ,&nbsp;Guojun Zhang ,&nbsp;Tao Yu ,&nbsp;Gang Wang","doi":"10.1016/j.seizure.2025.03.016","DOIUrl":"10.1016/j.seizure.2025.03.016","url":null,"abstract":"<div><h3>Objective</h3><div>Wearable devices are effective for detecting generalized tonic-clonic seizures (GTCS). However, many daily activities are often misclassified as GTCS, leading to a decline in user confidence. This study recommends utilizing wristband three-axis accelerometer (ACC), three-axis gyroscope (GYRO), and surface electromyography (sEMG) signals for GTCS detection and presents a novel seizure detection algorithm that offers high sensitivity and a reduced false alarm rate (FAR).</div></div><div><h3>Methods</h3><div>Inpatients with epilepsy and out-of-hospital healthy subjects were recruited and required to wear a wristband device to collect wristband signals. The proposed algorithm comprises five steps: preprocessing, motion filtering, feature extraction, classification, and postprocessing. The variations in performance across different signal combinations were compared. Additionally, the impact of training the model using only inpatient data versus the complete dataset on the algorithm's performance was also investigated.</div></div><div><h3>Results</h3><div>Wristband signals were collected from 45 patients and 30 healthy subjects, encompassing a total of 3367.3 h and including 60 GTCS. The proposed algorithm achieved 100 % sensitivity and a FAR of 0.1070/24 h. It demonstrated higher sensitivity and lower FAR compared to combinations with fewer signal modalities. In addition, the model trained on only in-hospital data demonstrates high sensitivity (98.33 %) and high FAR (0.9845/24 h).</div></div><div><h3>Significance</h3><div>The algorithm proposed for detecting GTCS using wristband ACC, GYRO, and sEMG signals achieved encouraging results, demonstrating the feasibility of this signal combination. Furthermore, incorporating out-of-hospital data into model training proved to be an effective solution for reducing FAR, which could facilitate the clinical application of seizure detection algorithms.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"127 ","pages":"Pages 127-134"},"PeriodicalIF":2.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143703955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loss-of-function variant in KCNH3 is associated with global developmental delay, autistic behavior, insomnia, and nocturnal seizures","authors":"Christiane K. Bauer ,&nbsp;Fanny Kortüm ,&nbsp;Anna Möllring ,&nbsp;Lev Grinstein ,&nbsp;Jonas Denecke ,&nbsp;Malik Alawi ,&nbsp;Robert Bähring ,&nbsp;Frederike L. Harms","doi":"10.1016/j.seizure.2025.03.014","DOIUrl":"10.1016/j.seizure.2025.03.014","url":null,"abstract":"<div><h3>Introduction</h3><div>The <em>KCNH</em> gene family encodes voltage-gated potassium (Kv) channels of the EAG subtype covering three subfamilies (Kv10–12). EAG channels are involved in the control of cardiac and neuronal excitation, and pathogenic variants in <em>KCNH</em> genes encoding Kv10 (eag) and Kv11 (erg) subfamily members cause a broad clinical spectrum ranging from cardiac arrhythmia to neurodevelopmental syndromes. However, no pathogenic variants have been hitherto reported for <em>KCNH</em> genes encoding Kv12 (elk) subfamily members.</div></div><div><h3>Methods</h3><div>Clinical, genomic, and functional studies were performed, including voltage-clamp experiments using heterologous channel expression in <em>Xenopus</em> oocytes.</div></div><div><h3>Results</h3><div>We examined an eight-year-old girl presenting with global developmental delay, intellectual disability, autistic and aggressive behavior, hyperactivity, insomnia, and nocturnal seizures. Focal seizures were successfully treated with sulthiame, which reduced the occurrence of temporo-parietal spike-wave paroxysms. Trio exome sequencing revealed a heterozygous <em>de novo</em> missense variant, NM_012284.3:c.1112C&gt;<em>T</em>; p.(Ala371Val), in <em>KCNH3</em>, which encodes the Kv channel α-subunit Kv12.2. The amino acid substitution associated with the <em>KCNH3</em> variant identified in the patient is located at a site highly conserved in EAG channels. The analogous variant in <em>KCNH2</em> causes long-QT-syndrome 2, and has also been associated with epilepsy. Electrophysiological characterization of the <em>KCNH3</em> p.(Ala371Val) variant demonstrated loss-of-function of the mutant Kv12.2 channels and strongly reduced current amplitudes upon co-expression of wildtype and mutant channel subunits in a dominant-negative manner.</div></div><div><h3>Conclusion</h3><div>Our results propose <em>KCNH3</em>, which is primarily expressed in the nervous system, as a new disease gene associated with a neurodevelopmental phenotype including seizures.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 14-21"},"PeriodicalIF":2.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biallelic SCN1A variants with divergent epilepsy phenotypes","authors":"Rowan Pentz ,&nbsp;Rebecca Hough ,&nbsp;Chumei Li ,&nbsp;Mark Tarnopolsky ,&nbsp;Kevin Jones ,&nbsp;Rajesh RamachandranNair ,&nbsp;Robyn Whitney","doi":"10.1016/j.seizure.2025.03.009","DOIUrl":"10.1016/j.seizure.2025.03.009","url":null,"abstract":"<div><h3>Purpose</h3><div>Pathogenic <em>SCN1A</em> variants most commonly cause autosomal dominant Dravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+). However, rare homozygous <em>SCN1A</em> variants have also been reported. We report two new cases of homozygous <em>SCN1A</em> variants associated with divergent epilepsy phenotypes.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the charts of two unrelated patients with different homozygous <em>SCN1A</em> variants. We also reviewed all published cases of biallelic <em>SCN1A</em> pathogenic variants, focusing on the epilepsy phenotypes.</div></div><div><h3>Results</h3><div>Patient 1 had a homozygous c. 1676T&gt;A, (p. Ile559Asn) variant of uncertain significance, inherited from asymptomatic parents. Patient 1 exhibited early afebrile seizures controlled by first-line anti-seizure medications and no febrile seizures or status epilepticus, as well as profound developmental delay, macrocephaly, and mild dysmorphic features. Patient 2 had a homozygous pathogenic c. 4970G&gt;A, (p. Arg1657His) variant carried by asymptomatic parents. This patient presented with early, recurrent, and prolonged febrile seizures, moderate developmental delay, and motor dysfunction and was diagnosed with Dravet syndrome. We identified 16 further cases from the literature. Including our cases, 9/18 (50 %) were diagnosed with Dravet syndrome and 6/18 (33 %) with GEFS+. The mean age of seizure onset was 7 months (range 3–19 months). Phenotypes ranged from intact neurodevelopment with controlled epilepsy to profound developmental delay and refractory epilepsy.</div></div><div><h3>Conclusion</h3><div>These cases highlight and expand the phenotypic spectrum associated with biallelic <em>SCN1A</em> variants. While some patients present typically for Dravet/GEFS+, others may present with developmental delay in the absence of febrile seizures or status epilepticus. Further studies are needed to confirm genotype-phenotype relationships.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"127 ","pages":"Pages 88-93"},"PeriodicalIF":2.7,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: A case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence","authors":"Zafeirenia Vlakou ,&nbsp;Anna Keramida ,&nbsp;Vasiliki Kotsali-Peteinelli ,&nbsp;Alexandros Matsingos ,&nbsp;Maria Konstantinidi ,&nbsp;Maria Chondrogianni ,&nbsp;Georgios Tsivgoulis ,&nbsp;Anastasios Bonakis ,&nbsp;Panagiota-Eleni Tsalouchidou","doi":"10.1016/j.seizure.2025.03.012","DOIUrl":"10.1016/j.seizure.2025.03.012","url":null,"abstract":"<div><h3>Background</h3><div>Cenobamate (CNB) has demonstrated remarkable efficacy in the treatment of drug-resistant focal epilepsy (FE). However, its role in other epilepsy types - such as drug-resistant generalized epilepsies (GEs), combined generalized and focal epilepsies (CGFEs), and developmental and epileptic encephalopathies (DEEs) - remains poorly explored. This article assesses the current evidence of CNB efficacy in these often complex and challenging patient populations.</div></div><div><h3>Methods</h3><div>A case report is presented detailing a 22-year-old male with drug-resistant epilepsy with myoclonic-atonic seizures (EMAtS) who achieved seizure freedom on CNB. A systematic literature review was conducted to evaluate CNB's efficacy in GEs, CGFEs, and DEEs, summarizing seizure outcomes, adverse events (AEs), and dose-response relationships.</div></div><div><h3>Results</h3><div>The case report highlights a patient achieving 18 months of sustained seizure freedom and improved quality of life with tapering of concomitant antiseizure medications (ASMs). The systematic review included 32 patients from six studies. Overall, 59.4 % achieved <em>a</em> ≥ 50 % seizure reduction, and 9.4 % attained seizure freedom. Subgroup analysis showed ≥50 % reduction in 50 % of patients with Lennox-Gastaut syndrome (LGS) and 80 % with Dravet syndrome (DS), with seizure freedom rates of 20 % in DS and 50 % in epilepsy with eyelid myoclonia (EEM). AEs, primarily sedation and fatigue, were reported in 74 % of patients, while 31.25 % reduced or tapered off ASMs.</div></div><div><h3>Discussion</h3><div>CNB demonstrates potential efficacy in managing seizures across drug-resistant epilepsy syndromes, extending its established use beyond FE. Further prospective trials are needed to validate these findings and optimize dosing strategies.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 1-8"},"PeriodicalIF":2.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of low glycemic index diet on epileptic seizure frequency, oxidative stress, mental health, and health-related quality of life in children with drug-resistant epilepsy","authors":"Gamze Yurtdaş Depboylu ,&nbsp;Olgay Bildik ,&nbsp;Gülşah Kaner ,&nbsp;Pınar Gençpınar ,&nbsp;Nihal Olgaç Dündar","doi":"10.1016/j.seizure.2025.03.010","DOIUrl":"10.1016/j.seizure.2025.03.010","url":null,"abstract":"<div><h3>Aim</h3><div>There is a gap in the existing literature regarding the evaluation of the effects of low glycemic index diet (LGID) on Turkish patients with drug-resistant epilepsy (DRE), as well as the impact of an LGID on oxidative stress markers in this population. This study aimed to evaluate the efficacy of an LGID on seizure frequency, oxidative stress markers [malondialdehyde (MDA), paraoxonase-1 (PON-1), total antioxidant status (TAS), and total oxidant status (TOS)], mental health, and health-related quality of life (HRQOL) in Turkish children with DRE.</div></div><div><h3>Methods</h3><div>The study used a pre-post design without a control group and involved 34 children with DRE. Seizure frequency, dietary intake, anthropometry, and biochemical parameters were assessed at baseline and after 3 months of LGID treatment. Behavioral and emotional difficulties were assessed with the “Strengths and Difficulties Questionnaire (SDQ)”. The depressive symptoms were evaluated using the “Children's Depression Inventory (CDI)” and HRQOL was assessed with the “Pediatric Inventory of Quality of Life (PedsQL)”.</div></div><div><h3>Results</h3><div>Thirty of the 34 included children completed the three-month LGID treatment. By the study's end, 38.2 % (13/34) achieved &gt;50 % seizure reduction and 41.2 % (14/34) were seizure-free. Glucose (<em>p</em> &lt; 0.001), insulin (<em>p</em> = 0.005), CRP (<em>p</em> = 0.046), and triglyceride levels (<em>p</em> = 0.015) significantly decreased. MDA levels decreased (<em>p</em> &lt; 0.001), whereas PON-1 levels increased significantly (<em>p</em> = 0.035). There was a significant improvement in all subscales of the HRQOL (<em>p</em> &lt; 0.001), as well as the total HRQOL and CDI scores (<em>p</em> &lt; 0.001). According to the SDQ, the conduct problems, hyperactivity/inattention, and emotional symptoms scores were significantly decreased. There was a negative correlation between MDA (<em>r</em> = -0.512, <em>p</em> = 0.005) and LGID efficacy after 3 months of LGID. Serum levels of MDA and glucose were positively correlated (<em>r</em> = 0.412, <em>p</em> = 0.033).</div></div><div><h3>Conclusion</h3><div>LGID shows promise in reducing seizures and improving oxidative stress, mental health, and quality of life for pediatric DRE in the short term. Further research is needed to address the limitations (small sample size, no control group, etc.) and investigate LGID's long-term effects.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"127 ","pages":"Pages 57-65"},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel epilepsy phenotype associated with a pathogenic GABRG2 variant","authors":"Raid Hommady ,&nbsp;Vivek Pai ,&nbsp;Fay Zhai ,&nbsp;Ashish R. Deshwar ,&nbsp;Robyn Whitney ,&nbsp;Suvasini Sharma ,&nbsp;Puneet Jain","doi":"10.1016/j.seizure.2025.03.007","DOIUrl":"10.1016/j.seizure.2025.03.007","url":null,"abstract":"<div><div>None.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"127 ","pages":"Pages 101-104"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium channel blockers for the treatment of focal epilepsy: A Chinese expert consensus","authors":"Raowei Yan ,&nbsp;Hesheng Zhang ,&nbsp;Zhen Hong ,&nbsp;Weiping Liao ,&nbsp;Xuefeng Wang ,&nbsp;Yuping Wang ,&nbsp;Bo Xiao ,&nbsp;Yanchun Deng ,&nbsp;Meiping Ding ,&nbsp;Xiong Han ,&nbsp;Shuli Liang ,&nbsp;Weihong Lin ,&nbsp;Xiaorong Liu ,&nbsp;Xuewu Liu ,&nbsp;Xin Wang ,&nbsp;Tiancheng Wang ,&nbsp;Xiangqing Wang ,&nbsp;Xiaoshan Wang ,&nbsp;Peimin Yu ,&nbsp;Kai Zhang ,&nbsp;Dong Zhou","doi":"10.1016/j.seizure.2025.02.016","DOIUrl":"10.1016/j.seizure.2025.02.016","url":null,"abstract":"<div><h3>Purpose</h3><div>To provide consensus-based recommendations for the use of sodium channel blockers (SCBs) in the management of focal epilepsy.</div></div><div><h3>Methods</h3><div>A three-round modified Delphi procedure was conducted among a Delphi panel of 24 Chinese experts to build a consensus. A steering committee developed 9 statements related to SCBs for the treatment of focal epilepsy, and these statements were evaluated and voted upon by the expert panel.</div></div><div><h3>Results</h3><div>The expert panel achieved consensus on nine statements regarding the treatment recommendations for oxcarbazepine, lamotrigine, lacosamide, eslicarbazepine, topiramate, zonisamide and cenobamate in focal epilepsy patients and treatment adjustments for SCBs.</div></div><div><h3>Conclusion</h3><div>This is a Chinese expert consensus on the use of SCBs in focal epilepsy developed using the modified Delphi method. These recommendations can help clinicians in their practice and guide future research.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"127 ","pages":"Pages 105-114"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}